MK 8521
Alternative Names: MK-8521Latest Information Update: 05 Nov 2023
At a glance
- Originator Merck & Co
- Class Antihyperglycaemics
- Mechanism of Action Glucagon receptor agonists; Glucagon-like peptide-1 receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Type 2 diabetes mellitus
Most Recent Events
- 26 Jul 2022 Discontinued - Phase-I for Type 2 diabetes mellitus (In volunteers) in Belgium (SC) (Merck pipeline, July 2022)
- 26 Jul 2022 Discontinued - Phase-II for Type 2 diabetes mellitus in USA, Australia, Colombia, Guatemala, Israel, New Zealand, Spain (SC) (Merck pipeline, July 2022)
- 01 May 2019 Suspended - Phase-I for Type 2 diabetes mellitus (In volunteers) in Belgium (SC) (Merck pipeline, May 2019)